Tonix Pharmaceuticals announces closing of $15,000,000 public offering
Tonix Pharma announced the closing of its underwritten public offering with total gross proceeds of $15,000,000. The Company expects to use the net proceeds from this offering to help fund the new Phase 3 RECOVERY study using a modified trial design for its lead product candidate, Tonmya®. December 11, 2018